RP Management, LLC
- SEC CIK
- 0001507673
- Latest filing
- Aug 6, 2025
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 17, 2021. Long positions only.
- Positions
- 4
- No 13F data for Q4 2020
- Portfolio value
- $244.5M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BHVNBiohaven Ltd. | COM | 2,111,111 | $144.3M | 59.0% | – | – | History |
| EPZMEpizyme, Inc. | COM | 9,166,667 | $79.8M | 32.7% | – | – | History |
| CYTKCytokinetics Inc | COM NEW | 875,656 | $20.4M | 8.3% | – | – | History |
| VIRXViracta Therapeutics, Inc. | COM | 3,700 | $34.0K | <0.1% | – | – | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| Epizyme Inc29428V904 | CALL | – | $21.9M |